Cooper Tobin

[Cooper Tobin @cooper_tobin]

@toy59496 Also readouts from study are expected prior to study completion (estimated during 2027).

[Cooper Tobin @cooper_tobin]

@toy59496 Andreas has stated the CLEAR study will be expanded to multiple sites, MGH was just the first to get the paper work done.

[Cooper Tobin @cooper_tobin]

@toy59496 (2) So it's management's stated direct-channel net. Agreed we can't confirm it's realised at scale channel mix, paid vs seeded and discounts withheld, and blended revenue/scan (~A$19–30) sits below, but CT:VQ receipts still to come as stated in last quarterly.

[Cooper Tobin @cooper_tobin]

@toy59496 (1) US$500 is not 2022 Stockhead figure. It's from June 2026: Fouras to Kohler (10 Jun) said of the US$650.50, "$500 to 4D, $150 to the hospital," and slide 9 of the 25 Jun Life Sciences Investor Forum deck prints "Less Payment to 4D US$500" (Bell Potter, 2 Jun, models the same)

[Cooper Tobin @cooper_tobin]

@toy59496 Robin - see Nilsen et al. which is precursor to CLEAR study. Showed automated classifier can detect PE from contrast-free CT:VQ perfusion images. 100% sensitivity, 68% specificity (lower specificity due to automatic detector used, not due to CT:VQ).

https://t.co/fIlQjbv2Ta